In a landmark move for obesity management in India, Novo Nordisk has officially launched Wegovy, the much-anticipated weight-loss drug that’s making waves globally. Designed as a once-a-week injection, Wegovy mimics the natural hormone GLP-1 in the body, helping reduce hunger, cravings, and control blood sugar—all crucial factors in managing obesity.
How Does Wegovy Work?
Wegovy contains semaglutide, an ingredient that activates GLP-1 receptors in the brain. This reduces appetite, makes you feel full sooner, and helps control cravings—making weight loss easier without extreme dieting or exhausting workouts.
In global trials, Wegovy users experienced an average 20% body weight loss within 68 weeks, along with a reduced risk of major heart problems such as stroke and heart attack.
Dosage & Pricing in India
Wegovy is available in five strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, administered via a user-friendly injection pen once a week. Prices start at ₹17,345 per month for the initial doses and go up to ₹26,015 for the full dose.
Why is this Important for India?
India ranks third globally in obesity rates, with nearly 29% of the population overweight or obese. Experts emphasize that obesity is not merely a lifestyle issue but a chronic disease influenced by multiple factors—including genetics and environment.
“Wegovy is more than just a slimming solution—it represents a medical breakthrough in chronic obesity care for India,” says Vikrant Shrotriya, MD, Novo Nordisk India.
Who Can Use Wegovy?
Adults with BMI of 30+, or
Adults with BMI 27+ with a related health condition (like diabetes or heart disease)
It requires a doctor’s prescription and must be taken under medical supervision.
A New Era in Obesity Treatment
With the launch of Wegovy, India joins countries like the US and UK in embracing medically-approved weight-loss solutions backed by science. It offers fresh hope for millions struggling with obesity and its associated health risks.
